An observational study in Dry Age-related Macular Degeneration, Macular Degeneration and Retinal Disease, sponsored by Gyroscope Therapeutics Limited. Terminated at 71 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Gyroscope Therapeutics Limited · Observational
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
Prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA due to AMD.
Secondary care.
Exclusion Criteria:
Geographic Atrophy (GA)
Change from baseline in area of Geographic Atrophy, as assessed by Fundus Auto Fluoresence measured in mm2
Time frame: Up to 96 weeks
Colour Fundus (CF)
Change from baseline in Colour Fundus Photography measured in mm2
Time frame: Up to 96 weeks
Retinal Drusen Volume
Change from baseline in retinal drusen volume measured in mm3
Time frame: Up to 96 weeks
Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA)
Change from baseline in ETDRS BCVA reading score
Time frame: Up to 96 weeks
Retinal sensitivity
Change from baseline in retinal sensitivity as assessed by microperimetry
Time frame: Up to 96 weeks
Visual Functioning Questionnaire
Change from baseline in National Eye Institute Visual Functioning Questionnaire 25-Items Version (NEI VFQ-25) Minimum Score (Best) = 29. Maximum score (Worst) = 149
Time frame: Up to 96 weeks
Medical Events of Interest (MEI)
Change from baseline in percentage of Participants with MEI
Time frame: Up to 96 weeks
Monocular and Binocular Reading Performance
Change in Monocular and Binocular Reading Performance measured in words/min
Time frame: Up to 96 weeks
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gyroscope Therapeutics Limited